Authorship
Clinical Trial Ethics
Communication
Conflict Interest
EPI_PH Issues
Guidlines
Lung CT
Peer Review
Precaution
Remune
Sig Tests_pval
Carvedilol
Stats Ethics
Subgroup Analyses
Vioxx
Writing
Anderson I, Avoiding plagiarism in academic writing, Nursing standard 2009, November. 23, 18, 35-37.
Burns D, Cut out the Plagiarism, Nursing standard 2009, Feb; 23(25):59-65.
Handa S. Plagiarism and publication ethics : Dos’ and don’ts. Indian J Dermatol Venereol Leprol 2008 Mar;74: 301-3
Abraham E.; Better infrastructure: Industry-academia partnerships---A marriage of convenience? Crit Care Med 2009; 37[Suppl.]:S159-S167
Barlett R.; Cornell R. Ethics and Statistics and Randomized Clinical Trials: Comment, Statistical Science 1991 Feb; 6(1): 63-65
Byar D. Ethics and Statistics and Randomized Clinical Trials: Comment, Statistical Science 1991 Feb; 6(1): 65-68
Dupont W. Ethics and Statistics and Randomized Clinical Trials: Comment, Statistical Science 1991 Feb; 6(1): 69-71
Fleming T.;
Sharples K.; McCall J; Moore A.; Rodgers A.; Stewart R.; Maintaining
Confidentiality of interim data to enhance trial integrity and
credibility, Clinical Trials 2008; 5:157-167
Fleming T; Identifying and Addressing Safety Signals in Clinical Trials, N Engl J Med 2009 Mar; 359:13
Fleming T; Clinical Trials: Discerning Hype From Substance, Ann Intern Med. 2010;153:400-406.
Hicks L.; Laupacis A.; Slutsky A.; Legal and Ethical Issues in Clinical
Research, A primer on data safety monitoring boards: mission, methods,
and controversies, Intensive care Med 2007; 33:1815-1818
Hilbrich L.; Sleight P.; Progress and
problems for randomized clinical trials: from streptomycin to the
era of megatrials, European Heart Journal 2006 Jan;27, 2158-2164
Levine R.; Ethics and Statistics in Randomized Clinical Trials: Comment,
Statistical Science 1991 Feb; 6(1): 71-74
Lindley F.; Ethics and Statistics in Randomized Clinical Trials:
Comment, Statistical Science 1991 Feb; 6(1): 74-77
Peppercorn J.; Buss W.; Fost N; Godley P.; The dilemma of data-safety
monitoring: provision of significant new data to research participants,
Lancet 2008 Feb; 371:527-529
Piantadosi; Rigor in Monitoring Clinical Trials is Ethical, Journal of Clinical Oncology 2008 Feb; 28 (4): 683-685
Royall R.; Ethics and Statistics in Randomized Clinical Trials:
Rejoinder, Statistical Science 1991 Feb; 6(1): 83-88
Royall R.; Ethics and Statistics in Randomized Clinical Trials,
Statistical Science 1991 Feb; 6(1): 52-62
Simes J.; Ethics and Statistics in Randomized Clinical Trials: Comment,
Statistical Science 1991 Feb; 6(1): 78-80
Slutsky A; Lavery J.; Sounding Board Data Safety and Monitoring Boards,
N Engl J Med 2009 Mar; 350(11):1143-1147
Wells R.; Data Safety and Monitoring Boards, N Engl J Med 2004 June; 350(23):2423
Wells R.; Secrecy and Integrity in Clinical Trials; Journal of Clinical Oncology 2008 Feb; 26(4):680-682
Zelen M.; Ethics and Statistics in Randomized Clinical Trials: Comment:
The Ethos of Clinical Trials, Statistical Science 1991 Feb; 6(1):81-83
Goldstein I.; Goldsteing M.; How Much Risk? A Guide to Understanding
Environmental Health Hazards, Cancer from Landfill? Oxford University
Press; 235-268
Conflict Interest:
Brennan T; Rothman D; Blank L.; Health Industry Practices That Create
Conflicts of Interest: A policy Proposal for Academic Medical Centers;
JAMA 2006 May; 295(4):429-433
Goldblum O.; Franzblau M.; Academic Medical Centers and Conflicts of
Interest; JAMA 2006 May;295(24):2844-2846
Carlat D.; Dr Drug Rep; The New York Times 2007 Nov.
Psaty B; Industry, Medicine, and Conflict of Interest: The View of a
Physician-Epidemiologist; CHRU 2008
DeAngelis C.; Conflict of Interest and the Public Trust; JAMA 2009 Apr;
284(17): 2237-2238
Deyo R; Psaty B; Simon G; Wagner E.; Omenn G.; The Messenger under
Attack – Intimidation of Researchers by Special-Interest Groups,
N Engl J Med 1997 April;336(16):1176-1180
Deyo R.; Bruce Psaty and the risks of calcium channel blockers;
Wal.Saf.Health Care 2002 Jul; 11:294-296
Elliott C.; The Drug Pusher, As America turns its health-care system
over to the market, pharmaceutical reps are wielding more and more
influence- and the line between them and doctors is beginning to blur;
Atlantic Monlthy 2006 Apr; 2-13
Fontanarosa P.; Rennie D.; DeAnglis C.; Postmarketing Surveillance-Lack
of Vigilance, Lack of Trust; JAMA 2004 Dec:209(21):2647-2650
Lo B.; Baldwin W.; Bellini L.; Bero L.; Campbell E.;Childress J.; Corr
P.; Dorman T.;Grady D.;Jost T.; Kelch R.;Krughoff R.; Loewenstein G.;
Perlmutter J.;Powe N.; Thompson D.; Williams D.; Conflict of Interest
in Medical Research, Education, and Practice; IOM 2009 April; 1-4
Korn D.; Conflicts of Interest in Biomedical Research; JAMA 2000 April; 284(17):2234-2237
DeAngelis C.; Fontanarosa P.; Conflict Over Conflicts of Interest, JAMA
2009 Mar:E1-E3
Psaty B.; Furberg C.; Ray W.; Weiss N.; Potential for Conflict of
Interest in the Evaluation of Suspected Adverse Drug Reactions, Use of
Cerivastatin and Risk of Rhabdomyolysis; JAMA 2004 Dec; 29(21):2622-2631
Psaty. B; Conflict of Interest, Disclosure, and Trial Reports; JAMA
2009 April; 301(14):1477-1479
Sah S.; Loewenstein G.; Effect of Reminders of Personal Sacrifice and
Suggested Rationalizations of Residents’ Self-Reported
Willingness to Accept Gifts: A Randomized Trial, JAMA 2010 Sep;
304(11):1204-1211
Turner E.; Matthews A.; Linardatos E.; Tell R.; Rosenthal R.; Special
Article ,Selective Publication of Antidepressant Trials and Its
Influence of Apparent Efficacy; N Engl J Med 2008 Jan;358:252-260
Turner E.; Tell R.; Selective Publication of Antidepressant Trials; N
Engl J Med 2008 May;328(20): 2181-2182
Boffetta P.; Mclaughlin J.; Vecchia C.; Tarone R.; Lipworth L.; Blot
W.; False-Positive Results in Cancer Epidemiology: A Plea for
Epistemological Modesty; JNCI 2008 July;100(14):988-995
Boffeta P. Mclaughlin J.; Lavecchia C.; Tarone R.; Lipworth L.; Blot
W.; Response; JNCI 2009 Feb; 101(3):213-214
Clapp R.; Hoppin P.; Kriebel D.; Erosion of the integrity of public
health science in the USA; Occup. Environ. Med.2006 April; 63:367-368
Clapp R.; Kriebel D.; Re: False-Positive Results in Cancer
Epidemiology: A Plea for Epistemological Modesty; JNCI 2009 Feb;
101(3):211-212
Crosigani P.; JNCI 2009 Feb; 101(3):212-213
Michaels D.; Industry groups are fighting government regulation by
formenting scientific uncertainty, Doubt is their product; SCIAM 2005
Jun; 96-101
Egilman D.; Scout; Corporate Corruption of Science- The case of
Chromium(VI); Int J Occup Environ Health 2006;12:169-176
Gilbert S.; Supplementing the Traditional Institutional Review Board
with an Environmental Health and Community Review Board; Environmental
Health Perspective 2006 Oct; 114(10): 1626-1629
Hansen S.; Krayer M.; Tickner J.; Categorizing Mistaken False Positives
in Regulation of Human and Environmental Health; Risk Analysis
2007;27(1): 255-269
Cranor C.; Science with health Consequences; Int J Occup Environ Health
2006 Apr/Jun; 12(2):177-179
Elgiman D.; Scout; Corporate corruption of Science- The Case of
Chromium(VI); Int J Occup Environ Health 2006 Apr/Jun;12:169-176
Kriebel D.; Tickner J.; Lemons J.; Levins R.; Loechler E.; Quinn M.;
Rudel R.; Schettler T.; Stoto M.; The Precautionary Principle in
Environmental Science; Environ Health Perspect 2001 Sep;109(9):871-876
Michaels D.; Scientific Evidence and Public Policy; American Journal of
Public Health 2005 Supp; 95(S1):S1-S7
Michaels D.; DOUBT Is Their Product; Scientific American 2005 Jun;292(6):96-101
Michaels D.; Monforton C.; Lurie P.; Commentary Selected science: an
industry campaign to undermine an OSHA hexavalent chromium standard; Environmental Health: A Global Acces Science Source 2006 Feb.
Monforton C.; Weigth of the Evidence or Wait for the Evidence?
Protecting Underground Miners From Diesel Particulate Matter; MJ of
Public Health 2006 Feb; 96(2): 271-276
Savage L.; Skepticism and Greater Awareness of Epidemiology’s
Limitation Could Reduce Impact of False-Positive Cancer Results; JNCI
2008
Ong E.; Glantz S.; Constructing “Sound Science” and
“Good Epidemiology”: Tobacco, Lawyers, and Public Relations
Firms; AJ of Public Health 2001 Nov; 91(11):1749-1757
Pacala S.; Bulte E.; List J.; Levin S.; Environmental Economics False
Alarm over Environmental False Alarms ; Science 2003 Aug;201:1187-1188
Pearce N.; Point-Counterpoint Corporate influences on epidemiology;
International Journal 2008 Jan; 37:46-53
Pearce N.; Response: The distribution and determination of
epidemiologic research; International Journal 2008; 37:65-68
Porta M; Speaker’s Corner, Persistent toxic substances :exposed
individuals and exposed populations; J Epidemiol Community Health
2004;58:534-535
Ryan M.; The Politics of Rish: A Human Rights Paradigm for
Children’s Environmental Health Research; Environmental Health
Perspective 2006 Oct: 114(10):1613-1616
Samet J; Burke T.; Turning Science Into Junk: The Tobacco Industry and
Passive Smoking; AJ of Public Health 2001 Nov;91(11): 1742-1744
Ebrahim S.; Lau E.; Commentary: Sick populations and sick individuals;
International Journal of Epidemiology 2001;30:433-434
Sharp R.; Ethical issues in Environmental health Research;
Environmental Health Perspectives 2003 Nov; 111(14):1786-1788
Vineis P.; Proof in observational medicine; J Epidemiol Community Health 1997 Jun; 51:9-13
Vineis P.; Viewpoint, The skeptical epidemiologist; International
Journal of Epidemiology 2009; 38:675-677
Weed D.; McKeown R.; Ethics and Environmental Health, Science and
Social Responsibility in Public Health; Environmental Health
Perspective 2003 Nov; 111(14):1804-1808
Yach D.; Bialous S.; Junking Science to Promote Tobacco; AJ of Public
Health 2009 Nov; 91(11):1745-1748
Altman DG,
Gore SM, Gardner MJ, Pocock SJ. Statistical Guidelines For
Contributors To Medical Journals. British Medical Journal ,
1983, 286:1489-1493
Bailar J.; Mosteller F.; Guidelines for Statistical Reporting in Articles for Medical Journals,
Amplification and Explanations; Annals of International Medicine 1988
Feb; 108:266-273
Ryan K.; Brady J.; Cooke R.; Height D.; Jonsen A.; King P.; Lebacqz K.;
Lousiell D.; Seldin D.; Sellar E.; Turtle R.; Regulations and Ethical
Guidelines, The Belmont Report Ethical Principles and Guidelines for
the protection of human subjects of research, The National Commission
for the Protection of Human Subjects of Biomedical and Behavioral
Research; Office of Human Subjects Research 2008
Benos D.; Kirk K.; Hall J.; How to Review a Paper; Advance In
Physiology Education 2003;27(2):47-52
Cummings P.; Rivara F.; Koepsell T.; Writing Informative Abstracts for
Journal Articles; Arch Pediatr Adolesc Med 2004 Nov;158:1086-1088
Drummond G.; Reporting ethical matters in The Journal of Physiology:
standards and advice; J Physiol 2009;587(4):713-719
Finney D.; Calibration Guidelines Challenge Outlier Practices; American
Statistical Association 2006 Nov; 60(4):309-314
LINK Procedural Guidelines Addressing Allegations of Scientific Allegations
of Scientific and Scholarly Misconduct, Policy for addressing
allegation of scientific and scholarly misconduct; Executive Order
2003; 4(9)
Iceland R.; ISI Declaration on Professional Ethics; Preamble, Values,
Principle and Background; International Statistics Institute
Eden L.; Jibs Code of Ethics; JIBS 2010 Feb.
LINK Committee on Science, Engineering, and Public Policy, National Academy
of Sciences, National Academy of Engineering, and Institute of
Medicine; On Being a scientist, A guide to responsible conduct in
research: Third Edition; NAP 2009;http://www.nap.edu/catalog/12192.html.
Neutra R.; Cohen A.; Fletcher T.; Michaels D.; Richter E.; Soskolne C.;
Toward Guidelines for the Ethical Reanalysis and Reinterpretation of
Another’s Research; Epidemiology 2006 May;17(3):335-338
Provenzale J.; Stanley R.; A Systematic Guide to Reviewing a Manuscript ; AJR 2005 Oct; 185:848-854
Provenzale J.; Stanley R; A Systematic Guide to Reviewing a Manuscript;
Journal of Nuclear Medicine Technology 2006;34(2):92-99
Cournand A.; The Code of the Scientist and Its Relationship to Ethics;
www.sciencemag.org; 1977 Nov; 699-705
The Regents of the University of Michigan; Policy Statement on the
Integrity of Scholarship and Procedures for Investigating Allegations
of Misconduct in the Pursuit of Scholarship & Research;
www.rackham.umich.edu/policies/gsh/add
LINK GME Vendor Interaction Policy; UW Medicine 2008
van Bele G.; Statistical Rules of Thumb: Second Edition; Univ of Washington
Vardeman S.; Morris M.; General Statistics and Ethics: Some Advice for
young Statisticians; The American Statistician 2003 Feb; 57(1): 21-26
Vardeman S.; Letters to the Editor; The American Statistician 2003 Aug;
57(3): 221-226
Vardeman S.; Morris; Letters to the Editor; The American Statistician
2003 Feb; 57(1): 319-321
McGaghie W.; Bordage G.; Shea J.; Scrandall S.; Caelleigh A.; Setinecke
A.; Pangaro L.; Regehr G; Penn G.; Review Criteria; Acad. Med.
2001;76(9):922-951
Altman D.; Statistical Reviewing for Medical Journals; Statist. Med. 1998; 17:2661-2674
Bacchetti P.; Peer review of statistics in medical research: the other
problem; BMJ 2002; 324:1271-1273
Bacchetti P.; Common Biostatistical Problems and How to Avoid Them
Benos D.; Kirk K.; Hall J.; How to review a paper; Advan in Physiol Edu 2003;27:47-52.
Provenzale J.; Stanley R.; A Systematic Guide to Reviewing a Manuscript; AJR 2005;185:848-854
Provenzale J.; Stanley R.; A Systematic Guide to Reviewing a
Manuscript; Journal of Nuclear Medicine Technology 2006;34(2):92-99
Resnik D.; The Precautionary Principle and Medical Decision Making; Journal of Medicine and Philosophy 2004; 29(3):281-299
Kahn JO, Cherng DW, Mayer K, Murray H, Lagakos S Evaluation of
HIV-1 immunogen, an immunologic modifier, administered to patients
infected with HIV having 300 to 549 x 10(6)/L CD4 cell counts: A
randomized controlled trial. JAMA. 2000 Nov 1;284(17):2193-202.
Churdboonchart, V., C. Sakondhavat, S. Kulpradist, B. Isarangkura Na
Ayudthya, V. Chandeying, S. Rugpao, C. Boonshuyar, W.
Sukeepaisarncharoen, W. Sirawaraporn, D. J. Carlo, and R. Moss. 2000. A
double-blind, adjuvant-controlled trial of human immunodeficiency virus
type 1 (HIV-1) immunogen (Remune) monotherapy in asymptomatic,
HIV-1-infected Thai subjects with CD4-cell counts of >300. Clin.
Diagn Lab Immunol. 7:728-733
Glidden D, Kim S, Lagakos S. Effectiveness of Remune. Clin
Diagn Lab Immunol. 2001 Mar;8(2):468-9.
LINK Research Agreement.
Birch. D, Cohn. G, Standing up to Industry. Chicago Tribune 2001, June 26.
DeAngelis C, Conflict of Interest and the Public Trust. JAMA 2000 April; 284(17):2237-2238
Niiler E, Business and Regulatory News, Company, Academics Argue Over
Data. Nature America Inc. 2000 Dec; 8
Altman D.; Bland M.; Statistics notes: Absence of evidence is not
evidence of absence; BMJ 1995 Feb;311;485
Hubbard R.; Armstrong S.; Why We Don’t Really Know What
Statistical Significance Means; Implications for Educators; Journal of
Marketing Education 2006 Aug; 28(2):114-120
Bacchetti P.; Common Biostatistical Problems And How to Avoid Them;
Biostatiscal Methods III 2005 Apr.
Bacchetti P.; Current sample size conventions: Flaws, harms, and
alternatives; BMC Medicine 2010: 8:17
Cohen J.; The Earth is Round(p < .05); American Psychologist 1994 Dec; 997-1003
Everett D.; Multiple comparisons: philosophies and Illustrations; Am J
Physiol Regulatory Integrative Comp Physiol 2000;279:R1-R8
Gelman A.; Stern H.; The Difference Between “Significant”
and “Not Sinigficant” is not Itself Statistically
Significant; American Statistical Association 2006 Nov.; 60(4): 1-4
Goodman S.; Toward Evidence-Based Medical Statistics. 1: The P Value
Fallacy; An Intern Med. 1999;130:995-1004
Louis T.; Zeger S.; Effective communication of standard errors and
confidence intervals; Biostatistics 2009 Jun; 10(1):1-2
Rothman K.; No Adjustments Are Needed for Multiple Comparisons;
Epidemiology 1990 Jan; 1(1):43-46
Schevish M.; P Values: What They Are and What They Are Not; The
American Statistician 1996 Aug; 50(3):203-206
Carvedilol:
Fisher LD, Moye LA. Carvedilol and the Food and Drug Administration
approval process: an introduction. Controlled Clin Trials 1999;20:1-15.
Fisher LD. Carvedilol and the FDA approval process: the FDA paradigm
and reflections upon hypothesis testing. Controlled Clin Trials
1999;20:16-39.
Moye L. Endpoint interpretation in clinical trials: the case for discipline. Controlled Clin Trials 1999;20:40-49.
Fisher LD. Carvedilol and the FDA approval process: a brief response to
Professor Moye’s article. Controlled Clin Trials 1999;20:50-51.
Packer M, Bristow MR, Cohn JM, et al. The effect of carvedilol on
morbidity and mortality in patients with chronic heart failure. U.S.
Carvedilol Heart Failure Study Group. N Engl J Med 1996;334:1349-1355.
back to top
Altman D.; Statistics and ethics in medical research, Misuse of
statistics is unethical; British Medical Journal 1980 Nov; 281:1982-1984
Altman D.; Statistics and ethics in medical research, Study Design;
British Medical Journal 1980 Nov;281:1267-1269
Altman D.; Statistics and ethics in medical research, How Large a
Sample; British Medical Journal 1980 Nov; 281:1336-1338
Altman D.; Statistics and ethics in medical research, Collecting and
Screening Data; British Medical Journal 1980 Nov; 281:1399-1400
Altman D.; Statistics and ethics in medical research, V-Analysing Data;
British Medical Journal 1980 Nov; 281:1473-1475
Altman D.; Statistics and ethics in medical research, VI-Presentation
of result; British Medical Journal 1980 Nov; 281:1542-1544
Altman D.; Statistics and ethics in medical research, VII-Interpreting
results; British Medical Journal 1980 Nov; 281:1612-1614
Altman D.; Statistics and ethics in medical research, VIII-Improving
the quality of statistics in medical journals; British Medical Journal
1980 Nov;
281:44-47
Altman D.; Bland M.; Statistics notes: Absence of evidence is not
evidence of absence; BMJ 1995; 311:485
Bailar J.; How to distort the scientific record without actually lying:
truth, and the arts of science, Come alterare la documentazione
scientifica seza in realta falsificalar: la verita e le arti della
scienza; Eur. J. Oncol.2006; 11(4):217-224
Gardenier J.; ASA Ethics Case Study #1, “After the Fact”
Co-author?; Toward a Statistical Ethics Casebook 1998 May.
AAMC Data Selection and Retention.Teaching the Responsible Conduct of Research Through a Case Study Approach, pp 23-34
Chan A.; Hrobjartsson A.; Jorgensen K.; Gotzche P.; Altman D.;
Discrepancies in sample size calculations and data analyses reported in
randomized trials: comparison of publications with protocols; BMJ 2008
Dec;337:a229
Curran-Everett D.; Benos D.; Guidelines for reporting
statistics in journals published by American Physiological Society;
Physiol Genomics 2004; 18:249-251
Curran-Everett D.; Benos D.; Guidelines for reporting statistics in
journal published by the American Physiological Society: the sequel;
Adv physiol Educ 2007; 31:295-298
Curran-Everett D.; Benos D.; Last Word on Perspectives
“Guidelines for reporting statistics in journals published by the
American Physiological Society: the sequel”; Adv Physiol Educ
2007; 31:306-307
DeMets D.; Statistics and Ethics in Medical Research; Science and
Engineering Ethics 1999; 5(1):97-117
Deming W.; Special Paper, Principles of Professional Statistical Practice; 1887-1900
Dwan K.; Altman D.; Arnaiz J.; Bloom J.; Chan A.; Cronin E.; Decullier
E.; Easterbrook P.; Elm E.; Gamble C.; Ghersi D.; Loannidis J.; Simes
J.; Williamson P.; Systematic Review of the Empirical Evidence of Study
Publication Bias and Outcome Reporting Bias; PLoS ONE 2008 Aug;
3(8):2-31
Dwan K.; Gamble C.; Williamson P.; Altman D.; Reporting of clinical
trials: a review of research funders’ guidelines; Trials 2008;9:66
Gardenier J.; Resnik D.; The Misuse of Statistics: Concepts, Tools, and
a Research Agenda; Accountability in Research 2002; 9:65-74
Gardner M.; Machin D.; Campbell M.; Use of check lists in assessing the
statistical content of medical studies; BMJ 1986; 292:810-812
Glantz S.; Biostatistic: how to detect, correct and prevent errors in
the medical literature; Circulation 1980; 61:1-7
Heilig C.; Weijerb C.; A critical history of individual and collective
ethics in the lineage of Lellouch and Schqwartz; Clin Trials 2005; 2:244
Holmes T.; Ten categories of statistical errors: a guide for reaserach
in endocrinology and metabolism; Am J Physiol Endocrinol Metab 2004;
286: E495-E501
Hutton J.; Medical Ethics and Statistics; CAM 2000
Morton J.; Reviewing scientific manuscripts: how much statistical
knowledge should a reviewer really know?; Adv Physiol Educ 2009; 33:7-9
Bookstein F.; Sampson P.; Suggested statistical standards for NTT
manuscripts: Notes from two of your reviewers; Neurotoxicology and
Teratology 2005; 27:407-415
Resnik D.; Statistics, Ethics, and Research: An Agenda for Education
and Reform; Accountability in Research 2000; 8:163-188
Rosenthal R.; Science And Ethics In Conducting, Analyzing, And
Reporting Psychological Research; Psych Sci 1994 May; 5 (3):127-135
Sackett D.; Bias In Analytic Research; J Chron Dis 1979; 32:51-63
Vardeman S.; Morris M.; Statistics and Ethics: Some Advice for Young
Statisticians; American Statistical Association 2003 Feb;
57(1):21-26
Elm E.; Altman D.; Reporting Guidelines: Looking Back From the Future;
Chest 2008 Oct; 134:682-684
Subgroup Analyses:
Martin G.; Munchausen’s Statistical Grid, Which Makes All Trials
Significant; Lancet 1984 Dec;
Rebbeck R.; Erratum, Re: “Pharmacogenetic Modulation Of Combined
Hormone Replacement Therapy By Progesterone-Metabolism Genotypes In
Postmenopausal Breast Cancer Risk”; Am J Epidemiol 2008;167:888
Rebbeck T.; Troxel A.; Normal S.; Bunin G.; DeMichele A.; Schinnar R.;
Berlin J.; Strom B.; Original Contribution, Pharmacogenetic Modulation
of Combined Hormone Replacement Therapy by Progesterone-Metabolism
Genotypes in Postmenopausal Breast Cancer Risk; Am J Epidemiol 2007
Sep; 166(12): 1392-1399
Weiss N.; Subgroup-Specific Associations in the Face of Overall Null
Results: Should We Rush In or Fear to Tread? Cancer Epidemiol
Biomarkers Prev 2008 Jun; 17(6): 1297-1299
Avorn J.; Evaluating Drug Effects in the Post-Vioxx World: There Must
Be a Better Way; Circulation 2006:113:2173-2176
DeAngelis C.; Fontanarosa P.; Impugning the Integrity of Medical
Science: The Adverse Effects of Industry Influence; JAMA 2008 Nov;
299(15):1833-1835
LINK Merck Withdraws Vioxx; FDA Issues Public Health Advisory; FDA Consumer
magazine 2004 Dec.
Horton R.; Vioxx, the implosion of Merck, and aftershock at the FDA;
Lancet 2004 Dec; 364:1995-1996
Juni P.; Nartey L.; Reichenbach S.; Sterchi R.; Dieepe P.; Egger M.;
Risk of cardiovascular events and rofecoxib: cumulative meta-analysis;
Lancet 2004; 364:2021-2029
LINK Vioxx: an unequal partnership between safety and efficacy; Lancet 2004
Oct; 364:1287-1288
Maxwell S.; Webb D.; COX-2 selective inhibitors-important lessons
learned; Lanchet 2005 Feb; 365:451-449
Psaty B.; Kronmal R.; Reporting Mortality Findings in Trials of
Rofecoxib for Alzheimer Disease or Cognitive Impairment: A Case Study
Based on Documents From Rofecoxib Litigation; JAMA 2008 Nov;
299(15):1813-1817
Curfman G.; Morrissey S.; Drazen J.; Expression of Concern Reaffirmed;
N Engl J Med 2006 Mar; 354(11):1193
Bombardier C.; Laine L.; Burgos-Vargas R.; Davis B.; Day R.; Ferraz M.;
Hawkey C.; Hochberg M; Kvien T.; Schnitzer T.; Weaver A.; Response to
Expression of Concern Regarding VIGOR Study; N Engl J Med 2006 Mar;
354(11):1196-1199
Ross J.; Hill K.; Egilman D.; Guest Authorship and Ghostwriting in
Publications Related to Rofecoxib: A Case Study of Industry Documents
From Rofecoxib Litigation; JAMA 2008 Nov; 299(15):1800-1812
Roth-Cline M.; Clinical Trials in the Wake of Vioxx: Requiring
Statistically Extreme Evidence of Benefit to Ensure the Safety of New
Drugs; Circulation 2006;113:2253-2259
Topol E.; Failing the Public Health-Rofecoxib, Merck, and the FDA; N
Engl J Med 2004 Oct; 352(17):1707-1709
Bombardier C.; Laine L.; Reicin A.; Shapiro D.; Burgos-Vargas R.; Davis
B.; Day R.; Ferraz M.; Hawkey C.; Hochberg M.; Kvien T.; Schnitzer T.;
Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naprozen
in Patients with Rheumatoid Arthritis; N Engl J Med 2000 Nov;
343(21):1520-1528
Curfman G.; Morrissey S.; Drazen J.; Expression of Concern: Bombardier
et al., “Comparison of Upper Gastrointestinal Toxicity of
Rofecoxib and Naprozen in Patrients with Rheumatoi Arthritis,” N
Engl Med 2000; 343:1520-8;N Engl Med 2005 Dec
Madigan D.; Secrets of Vioxx, Drug safety in the drug development process; Columbia Univ
Madigan D.; Safe and Effective? Drug safety in the drug development process; Columbia Univ.
Dodd J.; The ACS Style Guide, A Manual for Authors and Editors Second
Edition; American Chemical Society 1997
Buderer N.; Written Communication Skills for Consulting Statisticians
Creating a Collaborative environment with Clients; St. Vinc Mercy Med
Center.
Ehrenberg A.; The Problem of Numeracy; The American Statistician 1981 May; 35(2):67-71
Ehrenberg A.; Writing Technical Papers or Reports; The American
Statistician 1982 Nov; 36(4):326-329
Gopen G.; Swan J.; The Science of Scientific Writing; American
Scientist; 78
Gopen G.; Swan J.; The Science of Scientific Writing, If the reader is
to grasp what the writer means, the writer must understand what the
reader needs; American Scientist 1990 Nov; 78:550-558
Koschat M.; A Case for Simple Tables; The American Statistician 2005 Feb; 59(1):32-40
Rothman K.; Writing for Epidemiology; Epidemiology 1998 May; 9(3):333-337
Day R.; Academic Writing, Scientific Reports; Washington Univ.